Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 12/20 | 0.59 |
| ▸ | PTGDR | Q13258 | 10/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | ITGA4 | P13612 | 4/20 | 0.44 |
| ▸ | ITGB7 | P26010 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PHGDH | O43175 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12643159 | 0.91 | PTGER4 (0.49) | PTGER4PTGDRKDM4EALDH1A1LMNA | |
| SCHEMBL988169 | 0.81 | ACHE (0.44) | PTGER4KDM4EALDH1A1LMNAHPGD | |
| SCHEMBL12900354 | 0.81 | PTGER4 (0.85) | PTGER4PTGDR | |
| SCHEMBL12900381 | 0.78 | PTGER4 (0.68) | PTGER4PTGDRPHGDH | |
| SCHEMBL27855423 | 0.78 | PTGER4 (0.78) | PTGER4PTGDR | |
| SCHEMBL988305 | 0.78 | PTGER4 (0.78) | PTGER4PTGDR | |
| SCHEMBL987966 | 0.77 | PTGER4 (0.84) | PTGER4PTGDR | |
| SCHEMBL12900406 | 0.77 | PTGER4 (0.84) | PTGER4PTGDR | |
| SCHEMBL12900389 | 0.77 | PTGER4 (0.80) | PTGER4PTGDR | |
| SCHEMBL12585469 | 0.76 | PTGER4 (0.66) | PTGER4PTGDRPHGDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144153-A1 | AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-16 | — | — | US | disclosed |
| EP-2277858-A1 | AMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009139373-A1 | AMIDE COMPOUND | アステラス製薬株式会社 (JP) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144153-A1 | AMIDE COMPOUND | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGDR 13/4885KDM4E 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.